TY - JOUR
T1 - Systematic review of the efficacy, effectiveness and safety of recombinant haemagglutinin seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age
AU - O Murchu, Eamon
AU - Comber, Laura
AU - Jordan, Karen
AU - Hawkshaw, Sarah
AU - Marshall, Liam
AU - O’Neill, Michelle
AU - Ryan, Máirín
AU - Teljeur, Conor
AU - Carnahan, Annasara
AU - Pérez, Jaime Jesús
AU - Robertson, Anna Hayman
AU - Johansen, Kari
AU - Jonge, Jorgen de
AU - Krause, Tyra
AU - Nicolay, Nathalie
AU - Nohynek, Hanna
AU - Pavlopoulou, Ioanna
AU - Pebody, Richard
AU - Penttinen, Pasi
AU - Soler-Soneira, Marta
AU - Wichmann, Ole
AU - Harrington, Patricia
N1 - Publisher Copyright:
© 2022 John Wiley & Sons Ltd.
PY - 2023/5
Y1 - 2023/5
N2 - The most effective means of preventing seasonal influenza is through vaccination. In this systematic review, we investigated the efficacy, effectiveness and safety of recombinant haemagglutinin (HA) seasonal influenza vaccines to prevent laboratory-confirmed influenza. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials and non-randomised studies of interventions were eligible for inclusion. The search returned 28,846 records, of which 10 studies on recombinant HA influenza vaccine met our inclusion criteria. One study found that the quadrivalent recombinant HA influenza vaccine had higher relative vaccine efficacy (rVE) in preventing laboratory-confirmed influenza during the 2014–15 season compared with traditional quadrivalent vaccination in adults aged ≥50 years (rVE = 30%, 95% CI 10%–47%, moderate-certainty evidence). In a subgroup analysis, higher rVE was reported for influenza A (rVE = 36%, 95% CI 14% to 53%), but not for B (non-significant). Another study reported higher efficacy for the trivalent recombinant HA vaccine compared with placebo (VE = 45%, 95% CI 19–63, 1 RCT, low-certainty evidence) in adults aged 18–55 years. With the exception of a higher rate of chills (RR = 1.33, 95% CI 1.03–1.72), the safety profile of recombinant HA vaccines was comparable to that of traditional influenza vaccines. The evidence base for the efficacy and effectiveness of recombinant HA influenza vaccines is limited at present, although one study found that the quadrivalent recombinant HA influenza vaccine had higher rVE compared with traditional quadrivalent vaccination in adults aged ≥50 years.
AB - The most effective means of preventing seasonal influenza is through vaccination. In this systematic review, we investigated the efficacy, effectiveness and safety of recombinant haemagglutinin (HA) seasonal influenza vaccines to prevent laboratory-confirmed influenza. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials and non-randomised studies of interventions were eligible for inclusion. The search returned 28,846 records, of which 10 studies on recombinant HA influenza vaccine met our inclusion criteria. One study found that the quadrivalent recombinant HA influenza vaccine had higher relative vaccine efficacy (rVE) in preventing laboratory-confirmed influenza during the 2014–15 season compared with traditional quadrivalent vaccination in adults aged ≥50 years (rVE = 30%, 95% CI 10%–47%, moderate-certainty evidence). In a subgroup analysis, higher rVE was reported for influenza A (rVE = 36%, 95% CI 14% to 53%), but not for B (non-significant). Another study reported higher efficacy for the trivalent recombinant HA vaccine compared with placebo (VE = 45%, 95% CI 19–63, 1 RCT, low-certainty evidence) in adults aged 18–55 years. With the exception of a higher rate of chills (RR = 1.33, 95% CI 1.03–1.72), the safety profile of recombinant HA vaccines was comparable to that of traditional influenza vaccines. The evidence base for the efficacy and effectiveness of recombinant HA influenza vaccines is limited at present, although one study found that the quadrivalent recombinant HA influenza vaccine had higher rVE compared with traditional quadrivalent vaccination in adults aged ≥50 years.
KW - Flublok
KW - influenza vaccine
KW - recombinant HA
UR - http://www.scopus.com/inward/record.url?scp=85124049199&partnerID=8YFLogxK
U2 - 10.1002/rmv.2331
DO - 10.1002/rmv.2331
M3 - Review article
C2 - 35106885
AN - SCOPUS:85124049199
SN - 1052-9276
VL - 33
JO - Reviews in Medical Virology
JF - Reviews in Medical Virology
IS - 3
M1 - e2331
ER -